Allergan

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Allergan (AGN) delivered earnings and revenue surprises of 0.00% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Allergan (AGN) Q3 Earnings Meet Estimates

Shares of Allergan PLC AGN, +0.29% rose 0.5% in premarket trading Tuesday, after the drugmaker reported third-quarter earnings that beat expectations.

Allergan's stock gains after adjusted profit, revenue beat expectations

On Tuesday, November 5, Allergan (NYSE: AGN) will release its latest earnings report.

Allergan Q3 Earnings Preview

Catalent

Jazz Pharmaceuticals

Mylan

Regeneron Pharmaceuticals

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Allergan (AGN) Ahead of Earnings?

Allergan (AGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Allergan (AGN) Hits 52-Week High, Can the Run Continue?

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.

WIll Allergan (AGN) Beat Estimates This Earnings Season?

AbbVie

AbbVie Inc  said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc.

AbbVie says multiple parties vying for assets related to Allergan deal approval

Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Botox maker Allergan Plc AGN, -0.05% said Monday it expects to book a pre-tax charge of $750 million in the third quarter after its Forest subsidiaries settled an antitrust class action suit brought by direct purchasers of Namenda, a treatment for dementia associated with Alzheimer's disease.

Allergan to book $750 million pre-tax charge in Q3  after settlement of Navenda class-action suit

Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report?

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

Allergan PLC (NYSE: AGN) finally has announced that its shareholders have voted to approve the company’s acquisition by AbbVie Inc.

Are Allergan Shareholders Getting Enough in the AbbVie Acquisition?

Bristol-Myers

Zoetis

Pharma companies Allergan, Bristol-Myers Squibb and Zoetis could top the Street's third-quarter earnings expectations, an analyst said Thursday.

Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates

Brookfield Property REIT Inc. - Ordinary Shares - Class A

Brookfield Property Partners

Altria

My retirement portfolio goal is maximum safe long-term income, investing in quality companies bought at good to great prices, run by competent or excellent management teams I can trust.

Why I Have 28% Of My Retirement Portfolio Invested In These 3 High-Yield Blue Chips

In the latest trading session, Allergan (AGN) closed at $166.46, marking a -1.09% move from the previous day.

Allergan (AGN) Stock Moves -1.09%: What You Should Know

The U.S. Federal Trade Commission (FTC) has requested for more information from AbbVie Inc (ABBV.N) and botox maker Allergan Plc (AGN.N) on their $63 billion deal, the companies said on Friday.

FTC requests AbbVie, Allergan for more information on $63 billion deal

In the latest trading session, Allergan (AGN) closed at $166.69, marking a -0.1% move from the previous day.

Allergan (AGN) Stock Moves -0.1%: What You Should Know

The market is categorically bearish against major M&A deals.

AbbVie: The Allergan Merger Is Poised To Be More Accretive Than The Market Realizes

Johnson & Johnson

Sientra

As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

FDA Warns About Safety of Breast Implant: 3 Stocks at Risk (Revised)

FDA Warns About Safety of Breast Implant: 3 Stocks at Risk

Allergan (AGN) closed at $165.56 in the latest trading session, marking a -0.35% move from the prior day.

Allergan (AGN) Dips More Than Broader Markets: What You Should Know

About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

Allergan (AGN) closed the most recent trading day at $164, moving +1% from the previous trading session.

News for Allergan Stock (AGN)